Căutare | Ifvex

Ifvex

a adăugat un sunet Health
2025-02-06 05:37:12 -

Accelerating new drug development with AI in APAC
Clinical trials are becoming increasingly complex highlighting the need for efficiency. At the same time, electronic storage and computing power have increased dramatically and there are more opportunities for data sharing across industry stakeholders as patient data awareness is increasing. With these conditions, AI is poised to make scientific decisions easier and more reliable, therefore,...

0 Commentarii 0 Distribuiri 3K Views 0 previzualizare

Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
Ifvex

a adăugat un sunet Health
2025-01-15 14:06:04 -

Ant Group to connect 280,000 doctors on Haodf healthcare platform with 800M healthcare users on Alipay after acquisition
Following Ant Group’s acquisition of Haodf, a healthcare platform specializing in online doctor consultations, Ant Group President Cyril Han and Haodf.com Founder Hang Wang have jointly announced their plans to drive AI-powered healthcare innovations. Ant Group said in a statement on last Saturday that these efforts aim to help 280,000 doctors on the Haodf platform work more efficiently...

0 Commentarii 0 Distribuiri 5K Views 0 previzualizare

Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
Ifvex

a adăugat un sunet Health
2025-04-04 13:25:54 -

Li Ka Shing Foundation, Temasek Trust jointly commit $9M to acquire systems and advance clinical trial for innovative histotripsy cancer therapy in Singapore
The Li Ka Shing Foundation (LKSF) and Temasek Trust (TT) have committed S$12 million ($8.99 million) to bring innovative non-invasive ultrasound-based histotripsy tumor clinical trials to Singapore. The duo said in a statement on Friday that the National Cancer Centre Singapore (NCCS) and the National University Cancer Institute, Singapore (NCIS) will each receive one Histotripsy System...

0 Commentarii 0 Distribuiri 2K Views 0 previzualizare

Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!